Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CTH | P32929 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31120963 | 0.81 | ALDH1A1 (0.46) | KDM1ACA1CA2CA12CA9 | |
| SCHEMBL155344 | 0.80 | — | — | |
| SCHEMBL29957485 | 0.80 | KDM1A (0.39) | KDM1ACA1CA2CA12CA9 | |
| Hydrochloric Acid SCHEMBL1696071 | 0.78 | — | — | |
| SCHEMBL256677 | 0.77 | — | — | |
| SCHEMBL5155451 | 0.77 | — | — | |
| SCHEMBL13844956 | 0.77 | — | — | |
| SCHEMBL22286704 | 0.76 | MGAM (0.42) | KDM1ACA1CA2CA12CA9 | |
| SCHEMBL11260 | 0.76 | KDM1A (0.41) | KDM1ACA1CA2CA12CA9 | |
| SCHEMBL474814 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778569-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020099404-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2020-05-22 | — | — | WO | disclosed |
| US-10570157-B2 | Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2020-02-25 | — | — | US | disclosed |
| US-10570157-B2 | Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2020-02-25 | — | — | US | disclosed |
| US-20180215772-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | THE UNIVERSITY OF MANCHESTER (GB) | 2018-08-02 | — | — | US | disclosed |
| US-20180215772-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | THE UNIVERSITY OF MANCHESTER (GB) | 2018-08-02 | — | — | US | disclosed |
| US-20180215772-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | THE UNIVERSITY OF MANCHESTER (GB) | 2018-08-02 | — | — | US | disclosed |
| WO-2017017469-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | THE UNIVERSITY OF MANCHESTER (GB) | 2017-02-02 | — | — | WO | disclosed |
| EP-0220653-B1 | 3-AMINOCARBONYL-1,4-DIHYDROPYRIDINE-5-CARBOXYLIC ACID COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Nippon Shoji Kabushiki Kaisha (JP) | 1991-11-06 | — | — | EP | disclosed |
| US-4874773-A | HYPOTENSIVE AGENTS, VASODILATORS | NIPPON SHOJI KABUSHIKI KAISHA (JP) | 1989-10-17 | — | — | US | disclosed |
| EP-0220653-A2 | 3-Aminocarbonyl-1,4-dihydropyridine-5-carboxylic acid compounds, process for preparation and use thereof, and pharmaceutical composition containing the same | Nippon Shoji Kabushiki Kaisha (JP) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570157-B2 | Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors | NLRP3, IL1B, NOD1 | KDM1A 2482/4885CA1 4507/4885CA2 4416/4885 |
| US-20180215772-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | NLRP3, IL1B, NOD1 | KDM1A 2482/4885CA1 4507/4885CA2 4416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.